Alzheimer’s afflicts at least 6 million Americans. While only a subset may benefit from lecanemab, it holds enormous promise for those patients and their families — and for the many Alzheimer’s patients who will follow in the years to come. https://www.vox.com/policy/2023/7/7/23784663/alzheimers-drug-lecanemab-leqembi-full-fda-approval